Enliven Therapeutics Inc
(ELVN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2002 | 03-2002 | 12-2001 | 09-2001 | 06-2001 | |
| Gross Profit | 6,800 | 7,920 | 10,550 | 6,420 | 7,890 |
| Operating Expenses | 1,670 | 1,460 | 3,850 | 1,860 | 2,610 |
| Operating Income | -1,670 | -1,460 | -3,850 | -1,860 | -2,610 |
| Pre-tax Income | -1,670 | -1,460 | -3,850 | -1,860 | -2,610 |
| Net Income Continuous | -1,670 | -1,460 | -3,850 | -1,860 | -2,610 |
| Net Income | $-1,670 | $-1,460 | $-3,850 | $-1,860 | $-2,610 |
| EBITDA(a) | $-490 | $-170 | $-2,460 | $-780 | $-1,520 |